Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 11.26%, which has investors questioning if this is right time ...

Lexicon Bank proudly announces that Stacy Watkins, President and CEO, has been appointed to the Nevada State University ...

Event will feature insights on LX9211, Lexicon’s novel, investigational, non-opioid treatment, as well as expert panel and Q&A session on DPNPTHE WOODLANDS, Texas, Jan. 21, 2025 (GLOBE NEWSWIRE ...

Lexicon Bank is pleased to announce the promotion of Hilary Nelson to Executive Vice President. Since joining the bank as Senior Vice President in April 2020, Hilary has been a driving force behind Le ...

Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on LXRX stock, giving a Buy rating yesterday.Invest with Confidence: ...

Below, 10 key polyamory terms you may not be familiar with, but are definitely going to want to know. Oh, and because we’ve ...

We expect Lilly to continue to grow faster than the market, and model 60% 2025 Lilly GLP-1 sales growth. Lilly gained 5 points in US prescription share in 2024, and Zepbound’s 56% share of new ...

The M&A-focused Betaville blog sent an alert to subscribers highlighting a rumor regarding Lexicon (LXRX), contacts tell The Fly.Invest ...

THE WOODLANDS, Texas, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the company will host a virtual webcast: “LX9211 - Changing the Paradigm for ...